KZIA
Income statement / Annual
Last year (2023), Kazia Therapeutics Limited's total revenue was $555.00,
an increase of 2,120.00% from the previous year.
In 2023, Kazia Therapeutics Limited's net income was -$20.47 M.
See Kazia Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
Operating Revenue |
$555.00
|
$25.00
|
$15.18 M
|
$1,061.00
|
$1,565.00
|
$13,108.00
|
$8.79 M
|
$4.07 M
|
$89,000.00
|
$87,000.00
|
Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$555.00 |
$25.00 |
$15.18 M |
$1,061.00 |
$1,565.00 |
$13,108.00 |
$8.79 M |
$4.07 M |
$89,000.00 |
$87,000.00 |
Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Research and Development
Expenses |
$15.56 M
|
$20.25 M
|
$14.54 M
|
$9.49 M
|
$6.48 M
|
$9.77 M
|
$11.14 M
|
$9.89 M
|
$5.94 M
|
$2.48 M
|
General & Administrative
Expenses |
$8.58 M
|
$4.51 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
$4.27 M
|
Selling & Marketing
Expenses |
$0.00
|
$127,043.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$8.58 M
|
$4.64 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
$4.27 M
|
Other Expenses |
$0.00 |
-$10,000.00 |
$0.00 |
-$22,000.00 |
-$9,000.00 |
$3.67 M |
$0.00 |
$2.87 M |
$1.54 M |
$341,985.00 |
Operating Expenses |
$20.76 M |
$24.88 M |
$24.13 M |
$13.16 M |
$10.25 M |
$14.69 M |
$19.66 M |
$15.64 M |
$9.68 M |
$6.74 M |
Cost And Expenses |
$20.76 M |
$24.88 M |
$24.13 M |
$13.16 M |
$10.25 M |
$14.69 M |
$19.66 M |
$15.64 M |
$9.68 M |
$6.74 M |
Interest Income |
$22,558.00 |
$2,094.00 |
$42,240.00 |
$66,000.00 |
$100,000.00 |
$119,000.00 |
$276.00 |
$406,000.00 |
$89,261.00 |
$86,686.00 |
Interest Expense |
$0.00 |
$2,094.00 |
$0.00 |
$0.00 |
$2.19 M |
$0.00 |
$0.00 |
$0.00 |
$68,621.00 |
$714,524.00 |
Depreciation &
Amortization |
$1.87 M
|
$1.87 M
|
$1.27 M
|
$1.08 M
|
$1.08 M
|
$1.55 M
|
$1.41 M
|
$642,641.00
|
$574,964.00
|
$572,139.00
|
EBITDA |
-$22.28 M
|
-$24.74 M
|
-$5.11 M
|
-$11.44 M
|
-$7.30 M
|
-$17.69 M
|
-$9.44 M
|
-$11.72 M
|
-$7.48 M
|
-$5.74 M
|
EBITDA Ratio |
-40138.86 |
-989733.08 |
-0.34 |
-10783.22 |
-4661.98 |
-1349.86 |
-1.07 |
-2.88 |
-84.02 |
-66 |
Operating Income Ratio
|
-43507.26
|
-1067853.08
|
-0.42
|
-11804.9
|
-5354.63
|
-952.62
|
-1.23
|
-3.14
|
-91.47
|
-73.57
|
Total Other
Income/Expenses Net |
$3.41 M
|
$1.68 M
|
-$2.53 M
|
-$240,000.00
|
-$2.19 M
|
$8.22 M
|
-$16,161.00
|
$3.08 M
|
$2.35 M
|
-$197,916.00
|
Income Before Tax |
-$20.74 M |
-$25.02 M |
-$8.91 M |
-$12.77 M |
-$10.57 M |
-$6.34 M |
-$10.87 M |
-$12.16 M |
-$7.31 M |
-$7.57 M |
Income Before Tax Ratio
|
-37362.65
|
-1000635.8
|
-0.59
|
-12031.1
|
-6752.72
|
-483.98
|
-1.24
|
-2.99
|
-82.09
|
-87
|
Income Tax Expense |
$271,092.00 |
-$368,080.00 |
$484,347.00 |
-$298,000.00 |
-$298,000.00 |
-$305,000.00 |
$198,544.00 |
$2.77 M |
$1.44 M |
$955,103.00 |
Net Income |
-$20.47 M |
-$24.65 M |
-$8.42 M |
-$12.47 M |
-$10.27 M |
-$6.04 M |
-$10.67 M |
-$12.06 M |
-$7.14 M |
-$7.47 M |
Net Income Ratio |
-36874.2 |
-985912.6 |
-0.55 |
-11750.24 |
-6562.3 |
-460.71 |
-1.21 |
-2.96 |
-80.21 |
-85.83 |
EPS |
-1.12 |
-1.86 |
-0.0716 |
-1.71 |
-1.79 |
-1.25 |
-2.28 |
-2.82 |
-2.99 |
-4.76 |
EPS Diluted |
-1.11 |
-1.86 |
-0.0716 |
-1.71 |
-1.79 |
-1.25 |
-2.28 |
-2.82 |
-2.99 |
-4.76 |
Weighted Average Shares
Out |
$18.22 M
|
$13.25 M
|
$117.63 M
|
$7.31 M
|
$5.75 M
|
$4.84 M
|
$4.68 M
|
$4.27 M
|
$2.38 M
|
$1.57 M
|
Weighted Average Shares
Out Diluted |
$18.43 M
|
$13.25 M
|
$117.67 M
|
$7.31 M
|
$5.75 M
|
$4.84 M
|
$4.68 M
|
$4.27 M
|
$2.38 M
|
$1.57 M
|
Link |
|
|
|
|
|
|
|
|
|
|